MediciNova Statistics
Total Valuation
MediciNova has a market cap or net worth of $75.53 million. The enterprise value is $43.15 million.
Important Dates
The next estimated earnings date is Friday, November 14, 2025, after market close.
| Earnings Date | Nov 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
MediciNova has 49.05 million shares outstanding.
| Current Share Class | 49.05M |
| Shares Outstanding | 49.05M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 2.98% |
| Owned by Institutions (%) | 10.61% |
| Float | 42.08M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 292.89 |
| Forward PS | n/a |
| PB Ratio | 1.72 |
| P/TBV Ratio | 2.55 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 167.30 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.86, with a Debt / Equity ratio of 0.00.
| Current Ratio | 9.86 |
| Quick Ratio | 9.76 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -24.26% and return on invested capital (ROIC) is -16.77%.
| Return on Equity (ROE) | -24.26% |
| Return on Assets (ROA) | -15.82% |
| Return on Invested Capital (ROIC) | -16.77% |
| Return on Capital Employed (ROCE) | -30.23% |
| Revenue Per Employee | $19,840 |
| Profits Per Employee | -$923,872 |
| Employee Count | 13 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, MediciNova has paid $5,537 in taxes.
| Income Tax | 5,537 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -32.46% in the last 52 weeks. The beta is 0.47, so MediciNova's price volatility has been lower than the market average.
| Beta (5Y) | 0.47 |
| 52-Week Price Change | -32.46% |
| 50-Day Moving Average | 1.30 |
| 200-Day Moving Average | 1.41 |
| Relative Strength Index (RSI) | 60.07 |
| Average Volume (20 Days) | 2,934,968 |
Short Selling Information
The latest short interest is 756,440, so 1.54% of the outstanding shares have been sold short.
| Short Interest | 756,440 |
| Short Previous Month | 120,655 |
| Short % of Shares Out | 1.54% |
| Short % of Float | 1.80% |
| Short Ratio (days to cover) | 0.34 |
Income Statement
In the last 12 months, MediciNova had revenue of $257,918 and -$12.01 million in losses. Loss per share was -$0.25.
| Revenue | 257,918 |
| Gross Profit | 26,297 |
| Operating Income | -13.37M |
| Pretax Income | -12.00M |
| Net Income | -12.01M |
| EBITDA | -13.35M |
| EBIT | -13.37M |
| Loss Per Share | -$0.25 |
Full Income StatementBalance Sheet
The company has $32.56 million in cash and $180,751 in debt, giving a net cash position of $32.38 million or $0.66 per share.
| Cash & Cash Equivalents | 32.56M |
| Total Debt | 180,751 |
| Net Cash | 32.38M |
| Net Cash Per Share | $0.66 |
| Equity (Book Value) | 43.96M |
| Book Value Per Share | 0.90 |
| Working Capital | 29.59M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$9.72 million and capital expenditures -$2,897, giving a free cash flow of -$9.73 million.
| Operating Cash Flow | -9.72M |
| Capital Expenditures | -2,897 |
| Free Cash Flow | -9.73M |
| FCF Per Share | -$0.20 |
Full Cash Flow StatementMargins
| Gross Margin | 10.20% |
| Operating Margin | -5,185.49% |
| Pretax Margin | -4,654.50% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
MediciNova does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -15.90% |
| FCF Yield | -12.88% |
Analyst Forecast
The average price target for MediciNova is $7.00, which is 354.55% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $7.00 |
| Price Target Difference | 354.55% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -22.94% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
